Biotech Tests Pig-to-Human Transplants With New Funds
- EGenesis to use Crispr, gene-editing to attack organ crisis
- Investors include venture arms of Fresenius Medical, Bayer
This article is for subscribers only.
EGenesis, a biotech company working to alleviate the shortage of organs available for transplants, raised $100 million in new funding for its program that genetically edits organs from pigs so that they can be safely used in humans.
The investment, led by Fresenius Medical Care Ventures, brings funding for eGenesis to $138 million, with participation from new investors including Bayer AG’s investment arm, Leaps by Bayer, and Wellington Partners. Existing investors also participated including Arch Venture Partners and billionaire venture capitalist Vinod Khosla’s Khosla Ventures.